| Literature DB >> 30344288 |
Muhammad Rehan Sarwar1,2, Sadia Iftikhar3, Muhammad Sarfraz4.
Abstract
Objective: To evaluate influence of education level of older patients on polypharmacy, potentially inappropriate medications (PIMs) listed in Beer's Criteria, and unplanned hospitalization.Entities:
Keywords: Beer’s criteria; education level; older people; polypharmacy; potentially inappropriate medicines; unplanned hospitalization
Mesh:
Year: 2018 PMID: 30344288 PMCID: PMC6174342 DOI: 10.3390/medicina54040057
Source DB: PubMed Journal: Medicina (Kaunas) ISSN: 1010-660X Impact factor: 2.430
Characteristics of the participants.
| Variables | Education Level | |||||
|---|---|---|---|---|---|---|
| No Formal Education ( | Primary ( | Secondary ( | Tertiary ( | Total ( | ||
| Gender | Male | 77 (51.3) | 47 (74.6) | 98 (75.9) | 33 (76.7) | 255 (66.2) |
| Female | 73 (48.7) | 16 (25.4) | 31 (24.0) | 10 (23.3) | 130 (33.8) | |
| Age | 65–74 | 99 (66.0) | 39 (61.9) | 97 (75.1) | 27 (62.8) | 262 (68.1) |
| 75–84 | 39 (26.0) | 21 (33.3) | 28 (21.7) | 13 (30.2) | 101 (26.2) | |
| ≥85 | 12 (8.0) | 3 (4.8) | 4 (3.1) | 3 (6.9) | 22 (5.7) | |
| Civil Status | Single | 3 (2.0) | 4 (6.4) | 2 (1.6) | 1 (2.3) | 10 (2.6) |
| Married | 116 (77.3) | 55 (87.3) | 108 (83.7) | 33 (76.7) | 312 (81.0) | |
| Widow | 29 (19.3) | 4 (6.4) | 14 (10.9) | 8 (18.6) | 55 (14.3) | |
| Divorced | 2 (1.3) | 0 (0.0) | 5 (3.9) | 1 (2.3) | 8 (2.1) | |
| Employment Status | Employed | 37 (24.7) | 34 (53.9) | 98 (75.9) | 39 (90.7) | 208 (54.0) |
| Unemployed | 113 (75.3) | 29 (46.0) | 31 (24.0) | 4 (9.3) | 177 (45.9) | |
| Annual Income | Low class | 140 (93.3) | 55 (87.3) | 89 (68.9) | 5 (11.6) | 289 (75.1) |
| Middle class | 9 (6.0) | 8 (12.7) | 31 (24.0) | 15 (34.9) | 63 (16.4) | |
| Upper class | 1 (0.7) | 0 (0.0) | 9 (6.9) | 23 (53.5) | 33 (8.6) | |
| Residence | Rural | 84 (56.0) | 23 (36.5) | 22 (17.1) | 2 (4.7) | 131 (34.0) |
| Urban | 66 (44.0) | 40 (63.5) | 107 (82.9) | 41 (95.4) | 254 (65.9) | |
| Self- reported Health | Good | 8 (5.3) | 8 (12.7) | 10 (7.8) | 3 (6.9) | 29 (7.5) |
| Moderate | 80 (53.3) | 36 (57.1) | 92 (71.3) | 23 (53.5) | 231 (60.0) | |
| Poor | 62 (41.3) | 19 (30.2) | 27 (20.9) | 17 (39.5) | 125 (32.5) | |
| Health service utilization | Number of Clinic Visits of ≤3/year | 75 (50.0) | 30 (47.6) | 54 (41.9) | 13 (30.2) | 172 (44.7) |
| Number of Clinic Visits of ≥4/year | 75 (50.0) | 33 (52.4) | 75 (58.1) | 30 (69.8) | 213 (55.3) | |
| Health Risks | Smoking | 61 (40.7) | 28 (44.4) | 65 (50.4) | 18 (41.9) | 172 (44.7) |
| Alcohol Consumption | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (2.3) | 1 (0.3) | |
| Obesity | 34 (22.7) | 14 (22.2) | 36 (27.9) | 10 (23.3) | 94 (24.4) | |
| None | 55 (36.7) | 21 (33.3) | 28 (21.7) | 14 (32.6) | 118 (30.7) | |
| Co-morbidity | Present | 111 (74.0) | 44 (69.8) | 104 (80.6) | 36 (83.7) | 295 (76.6) |
| Absent | 39 (26.0) | 19 (30.2) | 25 (19.4) | 7 (16.3) | 90 (23.4) | |
| Number of Drugs | Four or less | 39 (26.0) | 19 (30.2) | 51 (39.5) | 18 (41.9) | 127 (32.9) |
| Polypharmacy (five to nine) | 103 (68.7) | 39 (61.9) | 70 (54.3) | 22 (51.2) | 234 (60.8) | |
| Excessive Polypharmacy (ten or more) | 8 (5.3) | 5 (7.9) | 8 (6.2) | 3 (6.9) | 24 (6.2) | |
| PIMS | Yes | 144 (96.0) | 55 (87.3) | 109 (84.5) | 34 (79.1)) | 342 (88.8) |
| No | 6 (4.0) | 8 (12.7) | 20 (15.5) | 9 (20.9) | 43 (11.2) | |
| Unplanned hospitalization | Yes | 97 (64.7) | 48 (76.2) | 52 (40.3) | 20 (46.5) | 217 (56.4) |
| No | 53 (35.3) | 15 (23.8) | 77 (59.7) | 23 (53.5) | 168 (43.6) | |
Indications associated with older hospitalized patients.
| Sr. | Indications | Education Level | |||||
|---|---|---|---|---|---|---|---|
| No Formal Education ( | Primary ( | Secondary ( | Tertiary ( | Total ( | |||
| 1 | CVS & Blood related | Ischemic heart diseases | 18 (12.0) | 9 (14.3) | 14 (10.9) | 11 (25.6) | 52 (13.5) |
| Arrhythmias | 34 (22.7) | 13 (20.6) | 32 (24.8) | 15 (34.9) | 94 (24.4) | ||
| Angina pectoris | 23 (15.3) | 6 (9.5) | 27 (20.9) | 2 (4.7) | 58 (15.1) | ||
| Total | 75 (50.0) | 28 (44.4) | 73 (56.6) | 28 (65.1) | 204 (52.9) | ||
| 2 | CNS | Insomnia | 6 (4.0) | 3 (4.8) | 4 (3.1) | 2 (4.7) | 15 (3.9) |
| Anxiety | 1 (0.7) | 1 (1.6) | 7 (5.4) | 2 (4.7) | 11 (2.9) | ||
| Total | 7 (4.7) | 4 (6.4) | 11 (8.5) | 4 (9.3) | 26 (6.8) | ||
| 3 | GIT | Dyspepsia | 11 (7.3) | 4 (6.4) | 3 (2.3) | 2 (4.7) | 20 (5.2) |
| Anorexia | 7 (4.7) | 3 (4.8) | 2 (1.6) | 0 (0.0) | 12 (3.1) | ||
| Gastritis | 2 (1.3) | 1 (1.6) | 3 (2.3) | 0 (0.0) | 6 (1.6) | ||
| Total | 20 (13.3) | 8 (12.7) | 8 (6.2) | 2 (4.7) | 38 (9.9) | ||
| 4 | Respiratory | Pneumonitis | 6 (4.0) | 9 (14.3) | 5 (3.9) | 0 (0.0) | 20 (5.2) |
| Dyspnea | 21 (14.0) | 6 (9.5) | 13 (10.1) | 4 (9.3) | 44 (11.4) | ||
| Pulmonary edema | 4 (2.7) | 7 (11.1) | 2 (1.6) | 0 (0.0) | 13 (3.4) | ||
| Pulmonary fibrosis | 7 (4.7) | 0 (0.0) | 4 (3.1) | 1 (2.3) | 12 (3.1) | ||
| Total | 38 (25.3) | 22 (34.9) | 24 (18.6) | 5 (11.6) | 89 (23.1) | ||
| 5 | Kidney | Urinary tract infections | 1 (0.7) | 0 (0.0) | 3 (2.3) | 0 (0.0) | 4 (1.0) |
| Nephritis | 0 (0.0) | 0 (0.0) | 1 (0.8) | 1 (2.3) | 2 (0.5) | ||
| Total | 1 (0.7) | 0 (0.0) | 4 (3.1) | 1 (2.3) | 6 (1.6) | ||
| 6 | Joint & Muscles related | Fractures | 2 (1.3) | 1 (1.6) | 5 (3.9) | 0 (0.0) | 8 (2.1) |
| Arthritis | 0 (0.0) | 0 (0.0) | 1 (0.8) | 0 (0.0) | 1 (0.3) | ||
| Total | 2 (1.3) | 1 (1.6) | 6 (4.7) | 0 (0.0) | 9 (2.3) | ||
| 7 | Endocrinology & metabolic disorders | Diabetes mellitus | 2 (1.3) | 0 (0.0) | 1 (0.8) | 0 (0.0) | 3 (0.8) |
| Thyroid disorders | 2 (1.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (0.5) | ||
| Total | 4 (2.7) | 0 (0.0) | 1 (0.8) | 0 (0.0) | 5 (1.3) | ||
| 8 | Others | 3 (2.0) | 0 (0.0) | 2 (1.6) | 3 (6.9) | 8 (2.1) | |
Potentially inappropriate medications (PIMs) prescribing pattern among study participants.
| Sr. | Medicines | ATC Code | No Formal Education ( | Primary ( | Secondary ( | Tertiary ( | Total ( | Trend |
|---|---|---|---|---|---|---|---|---|
| 1 | Aspirin | N02BA01 | 56 (37.3) | 28 (44.4) | 30 (23.3) | 11 (25.6) | 125 (32.4)) | High |
| 2 | Amlodipine | C08CA01 | 18 (12.0) | 9 (14.3) | 4 (3.1) | 1 (2.3) | 32 (8.3) | Medium |
| 3 | Alprazolam | N05BA12 | 5 (3.3) | 6 (9.5) | 4 (3.1) | 0 (0.0) | 15 (3.8) | Low |
| 4 | Atropine | A03BA01 | 8 (5.3) | 3 (4.8) | 0 (0.0) | 3 (7.0) | 14 (3.6) | Low |
| 5 | Aripiprazole | N05AX12 | 1 (0.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.2) | Low |
| 6 | Chlorpheniramine | R06AB04 | 1 (0.7) | 1 (1.6) | 2 (1.6) | 0 (0.0) | 4 (1.0) | Low |
| 7 | Clonazepam | N03AE01 | 1 (0.7) | 2 (3.2) | 0 (0.0) | 3 (7.0) | 6 (1.5) | Low |
| 8 | Chlorzoxazone | M03BB03 | 2 (1.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (0.5) | Low |
| 9 | Caffeine | N06BC01 | 1 (0.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.2) | Low |
| 10 | Chlorpromazine | N05AA01 | 0 (0.0) | 2 (3.2) | 0 (0.0) | 0 (0.0) | 2 (0.5) | Low |
| 11 | Diclofenac Sodium | M01AB05 | 9 (6.0) | 4 (6.3) | 9 (7.0) | 0 (0.0) | 22 (5.7) | Medium |
| 12 | Dimenhydrinate | R06AA52 | 4 (2.7) | 2 (3.2) | 2 (1.6) | 4 (9.3) | 12 (3.1) | Low |
| 13 | Digoxin | C01AA05 | 5 (3.3) | 3 (4.8) | 0 (0.0) | 0 (0.0) | 8 (2.0) | Low |
| 14 | Diphenhydramine | R06AA02 | 7 (5.3) | 2 (3.2) | 9 (7.0) | 5 (11.6) | 23 (5.9) | Medium |
| 15 | Diltiazem HCL | C08DB01 | 4 (2.7) | 1 (1.6) | 0 (0.0) | 0 (0.0) | 5 (1.2) | Low |
| 16 | Dexamethasone | R01AD03 | 3 (2.0) | 5 (7.9) | 0 (0.0) | 3 (7.0) | 11 (2.8) | Low |
| 17 | Doxazosin | C02CA04 | 0 (0.0) | 1 (1.6) | 0 (0.0) | 0 (0.0) | 1 (0.2) | Low |
| 18 | Ephedrine | R01AA03 | 2 (1.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (0.5) | Low |
| 19 | Esomeprazole | A02BC05 | 16 (10.7) | 3 (4.8) | 9 (7.0) | 5 (11.6) | 33 (8.5) | Medium |
| 20 | Famotidine | A02BA03 | 1 (0.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.2) | Low |
| 21 | Flurbiprofen | R02AX01 | 1 (0.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.2) | Low |
| 22 | Glimepiride | A10BB12 | 3 (2.0) | 2 (3.2) | 4 (3.1) | 0 (0.0) | 9 (2.3) | Low |
| 23 | Glibenclamide | A10BB01 | 7 (5.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 7 (1.8) | Low |
| 24 | Hydrocortisone | D07AA02 | 9 (6.0) | 4 (6.3) | 5 (3.9) | 4 (9.3) | 22 (5.7) | Low |
| 25 | Insulin | A10AB02 | 20 (13.3) | 13 (20.6) | 23 (17.8) | 11 (25.6) | 67 (17.4) | High |
| 26 | Ibuprofen | M01AE01 | 4 (2.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 4 (1.0) | Low |
| 27 | Ketorolac | M01AB15 | 1 (0.7) | 2 (3.2) | 0 (0.0) | 0 (0.0) | 3 (0.7) | Low |
| 28 | Methylprednisolone | D07AC14 | 2 (1.3) | 1 (1.6) | 0 (0.0) | 0 (0.0) | 3 (0.7) | Low |
| 29 | Metoclopramide | A03FA01 | 5 (3.3) | 2 (3.2) | 0 (0.0) | 0 (0.0) | 7 (1.8) | Low |
| 30 | Meloxicam | M01AC06 | 0 (0.0) | 1 (1.6) | 0 (0.0) | 0 (0.0) | 1 (0.2) | Low |
| 31 | Nifedipine | C08CA05 | 7 (5.3) | 1 (1.6) | 0 (0.0) | 0 (0.0) | 8 (2.0) | Low |
| 32 | Naproxen | M02AA12 | 3 (2.0) | 3 (4.8) | 0 (0.0) | 0 (0.0) | 6 (1.5) | Low |
| 33 | Omeprazole | A02BC01 | 30 (20.0) | 18 (28.6) | 28 (21.7) | 15 (34.9) | 91 (23.6) | High |
| 34 | Orphenadrine | N04AB02 | 9 (6.0) | 6 (9.5) | 0 (0.0) | 7 (16.3) | 16 (4.1) | Low |
| 35 | Piroxicam | M01AC01 | 4 (2.7) | 4 (6.3) | 0 (0.0) | 2 (4.7) | 10 (2.5) | Low |
| 36 | Promethazine | R06AD02 | 1 (0.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.2) | Low |
| 37 | Prednisolone | H02AB06 | 5 (3.3) | 4 (6.3) | 6 (4.7) | 3 (7.0) | 18 (4.6) | Low |
| 38 | Paroxetine | N06AB05 | 3 (2.0) | 1 (1.6) | 0 (0.0) | 0 (0.0) | 4 (1.0) | Low |
| 39 | Pantoprazole | A02BC02 | 1 (0.7) | 2 (3.2) | 0 (0.0) | 0 (0.0) | 3 (0.7) | Low |
| 40 | Ranitidine | A02BA02 | 5 (3.3) | 7 (11.1) | 5 (3.9) | 2 (4.7) | 19 (4.9) | Low |
| 41 | Rabeprazole | A02BC04 | 4 (2.7) | 2 (3.2) | 0 (0.0) | 0 (0.0) | 6 (1.5) | Low |
| 42 | Resperidone | N06AX08 | 1 (0.7) | 1 (1.6) | 0 (0.0) | 0 (0.0) | 2 (0.5) | Low |
| 43 | Tramadol | N02AX02 | 6 (4.0) | 2 (3.2) | 6 (4.7) | 4 (9.3) | 18 (4.6) | Low |
| 44 | Theophylline | R03DA04 | 5 (3.3) | 2 (3.2) | 3 (2.3) | 0 (0.0) | 10 (2.5) | Low |
Logistic regression analysis of educational level associated with polypharmacy, PIMs, and unplanned hospitalization.
| Independent Variable | Dependent Variable | OR | 95% CI | |||
|---|---|---|---|---|---|---|
| Yes | No | |||||
|
| ||||||
| Education Level | No formal education | 111 (28.8) | 39 (10.1) | 1.202 | 1.032–2.146 | 0.003 |
| Primary | 44 (11.4) | 19 (4.9) | 1.175 | 1.014–1.538 | 0.039 | |
| Secondary | 78 (20.3) | 51 (13.2) | 1.038 | 0.522–1.567 | 0.067 | |
| Tertiary | 25 (6.5) | 18 (4.7) | 1.0 | ----- | ----- | |
|
| ||||||
| Education Level | No formal education | 144 (37.4) | 6 (1.6) | 1.898 | 1.151–2.786 | 0.007 |
| Primary | 55 (14.3) | 8 (2.1) | 1.232 | 0.642–1.815 | 0.072 | |
| Secondary | 109 (28.3) | 20 (5.2) | 1.107 | 0.953–1.760 | 0.058 | |
| Tertiary | 34 (8.8) | 9 (2.3) | 1.0 | ----- | ----- | |
|
| ||||||
| Education Level | No formal education | 97 (25.2) | 53 (13.8) | 1.402 | 1.123–1.994 | 0.010 |
| Primary | 48 (12.5) | 15 (3.9) | 1.775 | 1.281–3.018 | <0.001 | |
| Secondary | 52 (13.5) | 77 (20.0) | 0.438 | 0.122–1.177 | 0.207 | |
| Tertiary | 20 (5.2) | 23 (6.0) | 1.0 | ----- | ----- | |